Full-year 2025 Research and Development (R&D) expenses increased to $160.6 million, up from $155.3 million in 2024. General and Administrative (G&A) expenses rose to $52.3 million for 2025, compared to $50.2 million in 2024. Net loss for the year ended December 31, 2025, widened to $201.1 million, from $195.9 million in 2024. Cash, cash equivalents, investments, and restricted cash totaled $191.4 million as of December 31, 2025, a decrease from $204.5 million at the end of 2024. The company projects its current cash position provides a runway into 2027. Prime Medicine is on track to file Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for its Wilson Disease program (PM577) in the first half of 2026 and for its Alpha-1 Anti-trypsin Deficiency (AATD) program (PM647) in mid-2026. Initial clinical data for both the Wilson Disease and AATD programs are expected in 2027. Ongoing engagement with the U.S. Food and Drug Administration (FDA) for PM359 in Chronic Granulomatous Disease (CGD) suggests existing clinical data may support an accelerated approval, with plans to submit a Biologics License Application (BLA). Preclinical proof-of-concept data for the Cystic Fibrosis (CF) program are anticipated in 2026. The collaboration with Bristol Myers Squibb for Prime Edited CAR-T products in hematology, immunology, and oncology continues.